Daprodustat approved indications and clinical uses

Daprodustat (Daprodustat) is an innovative oral drug belonging to the erythropoiesis-stimulating agent (ESA) class of drugs, used to treat anemia caused by chronic kidney disease (CKD), especially in adult patients who have been receiving dialysis for at least four months. The drug stimulates red blood cell production by mimicking hypoxia-responsive factor (HIF), a mechanism different from traditional erythropoietin (EPO). Due to its oral form, daprostat provides a convenient alternative for the treatment of anemia in chronic kidney disease, which is particularly important for patients who are long-term dependent on injectable drugs.

According to the US FDA prescribing information, daprostat did not significantly improve patients' quality of life, fatigue or health status. Therefore, it is not recommended as an alternative to blood transfusion in patients who urgently need to correct anemia. In addition, daprostat is not suitable for CKD patients who are not undergoing dialysis, which also limits its scope of indications.

A phase 3 clinical trial (NCT02879305) showed that in patients with chronic kidney disease receiving dialysis, dapocelot improved hemoglobin levels no significantly differently than a traditional erythropoiesis stimulating agent (ESA). The results of this trial show that daprostat is non-inferior to existing treatment options in treating anemia in dialysis patients, and that its oral form provides patients with a more convenient treatment option. However, given the drug's failure to significantly improve quality of life and fatigue symptoms, patients should still weigh the pros and cons on a case-by-case basis when choosing a treatment option.

Despite this, the market prospects for daplestat are still broad, especially among patients who cannot receive injections. The advantages of oral treatment may help more patients receive effective treatment. Especially in long-term treatment, daplestat provides patients with a more flexible and convenient treatment method, improving patient compliance and treatment continuity.

References: https://en.wikipedia.org/wiki/Daprodustat